Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $31.86 Average PT from Brokerages

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have earned an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $31.86.

BCAX has been the topic of several analyst reports. HC Wainwright dropped their price target on shares of Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Wedbush restated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.01 price target on shares of Bicara Therapeutics in a report on Thursday, March 13th. Wall Street Zen downgraded Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Finally, Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $25,000. CWM LLC acquired a new position in Bicara Therapeutics in the 1st quarter valued at $29,000. BNP Paribas Financial Markets acquired a new position in Bicara Therapeutics in the 4th quarter valued at $32,000. Legal & General Group Plc purchased a new position in Bicara Therapeutics in the 4th quarter valued at $33,000. Finally, Summit Investment Advisors Inc. acquired a new stake in Bicara Therapeutics during the 4th quarter worth $35,000.

Bicara Therapeutics Trading Down 2.7%

Shares of NASDAQ BCAX traded down $0.25 during trading hours on Thursday, hitting $9.18. 91,749 shares of the stock were exchanged, compared to its average volume of 581,623. Bicara Therapeutics has a 12 month low of $7.80 and a 12 month high of $28.09. The firm has a fifty day moving average price of $12.36 and a 200-day moving average price of $13.60.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.28). As a group, sell-side analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.